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Agmatine inhibits arginine vasopressin-stimulated urea trans- that agmatine exerts a variety of biological effects, nu-
port in the rat inner medullary collecting duct. merous functional roles have been proposed and among
Background. Agmatine, a putative endogenous ligand for these include roles associated with renal function [re-imidazoline receptors, induces numerous biological effects. The
viewed in 1].agonist clonidine binds to alpha-2 (2) adrenoceptors and imi-
Urea excretion by the kidney maintains nitrogen bal-dazoline receptors, and inhibits arginine vasopressin (AVP)-
stimulated urea permeability (Pu) in the rat inner medullary ance in mammals. The renal handling of urea results in
collecting duct (IMCD). Dexmedetomidine, a selective 2 ago- its accumulation in the medullary interstitium and plays a
nist, does not inhibit AVP-stimulated Pu. This study was con- significant role in concentrating the urine. Urea transportducted to determine if agmatine affects Pu in the rat IMCD
through the cells of the inner medullary collecting ductand to investigate the possibility of an imidazoline-mediated
mechanism. (IMCD) is the key mechanism that gets urea into the
Methods. The isolated-perfused tubule technique was used medullary interstitium. Arginine vasopressin (AVP) in-
to measure Pu in IMCDs from Wistar rats. AVP at 220 pmol/L creases urea permeability (Pu) in the IMCD by bindingor 8-chlorophenylthio cyclic adenosine monophosphate (8CPT
to the V2 receptor in the basolateral membrane and stim-cAMP) was used to stimulate Pu. Agmatine and other agents
ulating adenylyl cyclase [2, 3]. The alpha-2 (2) agonistwere added to the bath.
Results. Agmatine at 1 mol/L inhibited AVP-stimulated Pu clonidine, which also binds to imidazoline receptors, in-
by 50%. Agmatine-induced inhibition could not be separated hibits AVP-stimulated Pu in the IMCD [4]. Dexmede-completely from inhibition produced by the non-imidazoline, tomidine, another selective 2 agonist that does not bindcatecholamine epinephrine. Of three antagonists selective for
to imidazoline receptors does not inhibit AVP-stimu-2 adrenoceptors (rauwolscine, yohimbine, and RX821002), only
lated Pu [5, 6]. The question as to why dexmedetomidinerauwolscine reversed inhibition, whereas each of the three imida-
zoline-selective antagonists tested (atipamezole, idazoxan, and fails to affect Pu is unresolved. One possibility is the
BU239) produced a significant reversal. Agmatine did not af- involvement of imidazoline receptors.
fect basal Pu or inhibit 8CPTcAMP-stimulated Pu. Agmatine binds to both 2 and imidazoline receptorsConclusion. Our results indicate that agmatine inhibits AVP
and has been proposed to be an endogenous imidazolinestimulated Pu by a cAMP-dependent mechanism. Imidazoline
receptors are probably not involved. The possibility exists of an ligand [7]. We previously reported that agmatine failed to
unknown agmatine-selective receptor modulating urea trans- affect AVP-stimulated osmotic water permeability (Pf) in
port in the rat IMCD. the IMCD [8]. The purpose of this study was to investigate
the potential of agmatine to affect Pu in the IMCD and its
underlying mechanism. Results demonstrate that agmatine
Agmatine is a cationic amine compound that is formed inhibits AVP-stimulated Pu via a cyclic adenosine mono-from the decarboxylation of l-arginine by arginine de-
phosphate (cAMP)-dependent mechanism. Evidence sup-
carboxylase (ADC; Fig. 1). Since the mid-1990s it has
ports the involvement of an imidazoline-component but
been recognized that mammalian cells express agmatine
falls short of a separate imidazoline receptor-mediatedand its relative metabolic enzymes. From studies showing
mechanism.
Key words: AVP, urea permeability, IMCD, imidazoline receptor, 2 METHODSadrenoceptors, cyclic AMP.
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where Vo is the rate of fluid collection, A is the inner
surface area of the tubule, and Ci and Co are the activities
of [14C] urea (cpm/nL) in the initial luminal perfusate
and collected fluid, respectively. The reported Pu values
represent the averages of three individual samples taken
in each experimental period.
Experimental protocols
Once the IMCD was mounted on concentric pipettes,
perfusion was initiated and the bath temperature was
raised to 37C in 10 to 15 minutes. After an equilibration
period of 30 to 35 minutes, the sampling procedure for
the control period began. After three collections were
taken, an experimental agent was added to the bath fol-
lowed by 15 to 20 minutes of equilibration and the sam-
pling procedure. Other agents were added in subsequent
experimental periods followed by equilibration and theFig. 1. Metabolic pathways of agmatine. Agmatine is decarboxylated
sampling procedure. The sequence of a given protocolarginine and has a molecular weight of 228. Enzymes are shown in
boxes. Abbreviations are: ADC, arginine decarboxylase; NOS, nitric is shown on the abscissa of the graphs in the Results
oxide synthase; ODC, ornithine decarboxylase; DAO, diamine oxidase.
section.
To determine if agmatine affects AVP-stimulated Pu,
220 pmol/L AVP was added to the bath after the control
neys were rapidly removed and cut into small slices that period. The AVP period was followed by adding 1mol/L
were placed in chilled dissection solution of the same or 100 nmol/L agmatine to the bath and then removing
composition as the bathing solution or bath described agmatine in the final period. To determine if agmatine
below. IMCD segments were dissected and isolated from affected basal Pu, 1 mol/L agmatine was added afterthe terminal two-thirds of the inner medulla, that is, the the control period followed by adding AVP. In other
terminal IMCD [2, 11]. protocols the non-imidazoline, adrenergic agonist epi-
After isolation, the IMCD was transferred to a perfu-
nephrine was used with agmatine to determine if inhibi-
sion chamber on the stage of an inverted microscope
tion by both agents occurs via separate mechanisms.and mounted on concentric pipettes that suspended the
In another attempt to distinguish between imidazolinetubule in the bath. One end of the tubule was drawn by
versus adrenergic mechanisms, antagonists selective forsuction into the tip of one of the outer pipettes. The tip
2 or imidazoline receptors were used. Protocols beganof the inner pipette containing the luminal perfusion
with the control period followed by the AVP periodsolution, or perfusate, was advanced into the lumen of
followed by adding 1 mol/L agmatine to the bath. Thethe tubule and perfusion was initiated via air pressure.
final period was with the antagonist at 1 mol/L addedThe opposite end of the tubule was held in the tip of
to the bath. Three protocols were conducted with2 antag-another glass micropipette where the perfusate accumu-
onists (rauwolsicne, yohimbine, and RX821002) and threelated. The tip of this pipette was coated with a viscous
were conducted with imidazoline antagonists (idazoxan,silicone liquid (Sylgard 184; Dow Corning, Midland, MI,
atipamezole, and BU239).USA) in order to isolate the perfusate from the bath.
Samples of collected perfusate were taken periodically To determine if agmatine-induced inhibition was cAMP-
during an experiment with a constant-volume or volu- independent, 8-chlorophenylthio 3-5 cyclic adenosine
metric pipette. The composition of the bath and perfu- monophosphate (8CPTcAMP) at 104 mol/L was used
sate was as follows (in mmol/L): 115 NaCl, 25 NaHCO3, in lieu of AVP to stimulate Pu. Agmatine at 1 mol/L was
10 sodium acetate, 5 KCl, 1.0 CaCl2, 1.2 MgSO4, 1.2 then added to the bath in one protocol and in another,
NaH2PO4, 5.5 glucose, at pH 7.4. The solution was contin- agmatine at 100 and 500 mol/L was tested.
uously bubbled with 95% O2/5% CO2 gas. All experi-
ments were conducted at 37C. Source of biochemicals
Urea permeability was determined from the disap- Arginine vassopressin, 8CPTcAMP and epinephrine
pearance rate of 14C-urea (50 to 100 cpm/mL) from the
were purchased from Sigma Chemical Co. (St. Louis, MO,perfusate and calculated with the following equation:
USA). Agmatine was purchased from Tocris-Cooksin
(Ballwin, MO, USA). 14C inulin was purchased from NewPu 
Vo
A
ln
Ci
Co England Nuclear (Boston, MA, USA).
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Fig. 3. Agmatine does not affect basal Pu. Agmatine (Ag) was added
to the bath at 1 mol/L after the control period. AVP at 220 pmol/L
added to the bath with agmatine increased Pu (P  0.001) and Pu
decreased upon removal of AVP in the final period (P  0.001; see
Fig. 2 legend).
AVP-stimulated Pu by 60%, and the removal of epineph-
rine resulted in a small but significant increase in Pu
(Fig. 4A). In another protocol, 5 mol/L epinephrine
inhibited AVP-stimulated Pu by 39% and the addition
of 1 mol/L agmatine reduced Pu but not with statistical
significance (P  0.08; Fig. 4B). In the third protocol
(Fig. 4C), 100 mol/L agmatine inhibited Pu by 51% and
the addition of 5 mol/L epinephrine failed to reduce
Pu further.
Figures 5 and 6 show the effects of 2-selective and
Fig. 2. Agmatine inhibits arginine vasopressin (AVP)-stimulated urea imidazoline-selective antagonists on reversing the agma-
permeability (Pu). After the control period AVP at 220 pmol/L was tine-induced inhibition of AVP-stimulated Pu. Figure 5added to the bath. In both protocols, AVP significantly increased Pu shows that of the three adrenergic antagonists, only rau-(P  0.001). (A ) A total of 1 mol/L agmatine decreased Pu by 50%
of the AVP-stimulated level (P  0.001). (B ) A total of 100 nmol/L wolscine reversed inhibition whereas yohimbine and
agmatine did not significantly lower Pu (P  0.06). Each line represents RX821002 failed to do so. Figure 6 shows that each imida-
a single experiment. Mean SE are shown above each period. *Signifi-
zoline-selective antagonist, atipamezole, idazoxan, andcantly different from previous period.
BU239, significantly reversed inhibition.
Agmatine at 1 mol/L failed to inhibit Pu when stimu-
lated by 104 mol/L 8CPTcAMP (Fig. 7A) and in a subse-
Statistical analysis quent protocol (Fig. 7B), agmatine at 100 and 500mol/L
also failed to reduce 8CPTcAMP-stimulated Pu.Data were analyzed with a single-factor ANOVA with
repeated measures and P values between treatments were
determined using the SuperAnova statistical package.
DISCUSSION
P  0.05 was considered significant.
Until the mid 1990s it was generally believed that
agmatine and ADC were expressed only in plants and
RESULTS bacteria. While searching for the endogenous imidazo-
line ligand, Li et al identified agmatine and ADC inThe first objective was to determine if agmatine affects
Pu. Agmatine at 1 mol/L significantly inhibited AVP- the mammalian brain [7]. Since then, investigators have
proposed numerous functional roles for agmatine suchstimulated Pu by 50% (Fig. 2A) whereas inhibition with
100 nmol/L agmatine was not significant (P  0.06; Fig. as a central nervous system (CNS) neurotransmitter [1],
a modulator of opioid analgesia [12], a mediator of cell2B). Agmatine at 1 mol/L did not affect basal Pu (Fig. 3).
Figure 4 shows data from the combination of epineph- growth [13], a regulator of nitric oxide synthase [14, 15],
and a stimulator of histamine release in the stomach [16]rine and agmatine. The addition of both 1 mol/L epi-
nephrine and 1 mol/L agmatine to the bath inhibited and insulin release in the pancreas [17].
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Fig. 5. Effects of 2-adrenoceptor antagonists on agmatine-induced
inhibition of AVP-stimulated Pu. Results are shown of the final two
periods of three experimental protocols using the selective 2-antagonist
shown on the abscissa. Each protocol was conducted as before, that is,
the control period, followed by adding 220 pmol/L AVP, followed by
adding 1 mol/L agmatine, and then adding 1 mol/L antagonist. In
each protocol AVP increased Pu (P  0.001) and agmatine decreased
Pu (P  0.001). *Rauwolscine significantly reversed agmatine-induced
inhibition (P  0.01) whereas yohimbine and RX-821002 failed to
reverse the inhibition. (N  4 in each set of experiments). Symbols are:
( ) AVP 	 agmatine; ( ) AVP 	 agmatine 	 antagonist.
Fig. 4. Effects of epinephrine and agmatine on Pu. (A ) The addition
of 1 mol/L epinephrine (epi) with 1 mol/L agmatine to the bath
decreased AVP-stimulated Pu by 60% (P  0.001). The removal of
epinephrine in the final period increased Pu to 47% of the AVP-stimu-
lated level (P  0.001). (B ) The addition of 5 mol/L epinephrine to
the bath decreased AVP-stimulated Pu by 40% (P 0.001). Subsequent
addition of 1 mol/L agmatine did not significantly lower Pu. (C ) The Fig. 6. Effects of imidazoline-selective antagonists on agmatine-induced
addition of 100 mol/L agmatine decreased Pu by 51% and the addition inhibition of Pu. Each imidazoline-selective antagonist (atipamezole,
of 5 mol/L epinephrine failed to reduce Pu further (see Fig. 2 legend). idazoxan, and BU239) significantly reversed agmatine-induced inhibition
of AVP-stimulated Pu (P  0.01; N  4 in each protocol; see Fig. 5
legend). Symbols are: ( ) AVP 	 agmatine; ( ) AVP 	 agamatine 	
antagonist.
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The renal handling of urea plays a significant role in
urinary concentration. Urea accumulates in the renal
medullary interstitium via absorption in the terminal
IMCD, and AVP increases Pu in the IMCD by stimulat-
ing adenylyl cyclase [2, 3]. AVP also increases Pf in the
IMCD via the same basic receptor-mediated events lead-
ing to cAMP elevation [2]. Thus, it seems reasonable to
expect that any agent that affects AVP-stimulated Pf
would also affect Pu.
The aim of this study was to determine if agmatine
affects Pu in the rat IMCD and if so, to investigate the
mechanism. Because agmatine did not alter AVP-stimu-
lated Pf [8], we were surprised at the findings shown in
Figure 2 demonstrating that 1mol/L agmatine inhibited
AVP-stimulated Pu by 50%. At 100 nmol/L, agmatine
produced a slight but non-statistically significant reduc-
tion (Fig. 2B) and in another protocol described below,
100 mol/L agmatine inhibited Pu by 51%. Agmatine
did not affect basal Pu (Fig. 3), but interestingly, agmatine
appeared to produce greater inhibition when added be-
fore AVP and this could have important mechanistic
implications.
We speculated the involvement of imidazoline recep-
tors in agmatine-induced inhibition of Pu because of our
previous finding that the 2 agonist dexmedetomidine,
which is not selective for imidazoline receptors [5], did
not inhibit AVP-stimulated Pu although it did inhibit
AVP-stimulated Pf at concentrations in the nanomolar
range [6]. In addition, clonidine, which binds to both 2
adrenoceptors and imidazoline receptors, reduced AVP-
stimulated Pu in the rat IMCD [4, 25].
Because many imidazoline-selective agents bind to 2
adrenoceptors, investigators have used catecholamines
Fig. 7. Agmatine does not inhibit cAMP-stimulated Pu. (A ) Protocol like epinephrine and norepinephrine to mask adrenergicwas conducted as before except 104 mol/L 8CPTcAMP (cAMP) was
added to the bath in lieu of AVP. Agmatine at 1 mol/L did not inhibit receptors [23, 26–28]. We used epinephrine to determine
cAMP-stimulated Pu. (B ) Agmatine at 100 mol/L and 500 mol/L if the agmatine-induced inhibition of AVP-stimulated Pufailed to reduce cAMP-stimulated Pu (see Fig. 2 legend). could be separated from that produced by epinephrine.
Agmatine and epinephrine together (each at 1 mol/L)
reduced AVP-stimulated Pu by 60% and removal of epi-
nephrine significantly raised Pu to about 50% of the AVP-Agmatine also appears to have important roles in renal
function. Lortie et al reported an endogenous plasma ag- stimulated level, which is close to that shown in Figure 2A
(Fig. 4A). Agmatine at 1 mol/L failed to reduce AVP-matine concentration of about 1 mol/L in the rat and
significant ADC activity in kidney tissue [18]. In addition, stimulated Pu in the presence of 5 mol/L epinephrine
(Fig. 4B), and in a third group of experiments (Fig. 4C),exogenous agmatine increased single nephron glomeru-
lar filtration rate via an apparent imidazoline receptor- 5 mol/L epinephrine failed to reduce Pu in the presence
of 100 mol/L agmatine. Thus, in these three protocols,mediated mechanism. Recently, plasma agmatine concen-
tration in the rat was shown to be about 2.5 mol/L and only the first demonstrated any separation between ag-
matine and epinephrine-induced inhibition. In the pres-the estimated cellular level in renal tissue was markedly
higher, perhaps 100 to 500mol/L [19]. Penner and Smyth ent study agmatine at 1 mol/L produced greater inhibi-
tion than epinephrine at 5 mol/L (50 vs. 30%). In areported that agmatine infusion into the rat renal artery
increased urine flow rate, sodium excretion, and osmolar previous study we reported that epinephrine inhibited
Pu stimulated by a non-hydrolyzable cAMP analog indi-clearance [20]. They attributed the increased natriuresis
to agmatine activation of imidazoline receptors. Previous cating post-cAMP–dependent events [6]. In the present
study, agmatine clearly failed to inhibit cAMP-stimu-studies using pharmacological binding techniques identi-
fied imidazoline receptors in the rat kidney [21–24]. lated Pu (Fig. 7). While some evidence indicates mecha-
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nistic differences, inhibition by agmatine was not dissoci- dazoline receptor was recently initiated and results from
these studies will help identify specific receptor-mediatedated completely from that by epinephrine.
In 1984, Atlas and Burstein isolated a compound desig- mechanisms [39].
Since 2 adrenoceptors couple to an inhibitory G pro-nated clonidine-displacing substance (CDS) from the calf
brain [29]. Ernsberger et al reported that CDS binds to tein that decreases adenylyl cyclase activity [40], it is gener-
ally accepted that 2-mediated inhibition of AVP-stimu-imidazoline receptors in the rat kidney and suggested
that CDS is the endogenous ligand at these sites [22]. Li lated transport in the collecting duct occurs via reduction
of cellular cAMP levels. The finding that agmatine failedet al presented evidence demonstrating that agmatine
shared similar properties with that of CDS and suggested to inhibit Pu stimulated by 8CPTcAMP (Fig. 7) indicates
that the agmatine-induced inhibition occurs via pre-cAMP-that agmatine is an endogenous imidazoline ligand [7].
However, other studies indicate that agmatine and CDS dependent events and supports the classic 2-mediated
inhibitory model. In contrast, the 2/imidazoline agonistsare not the same, and it is yet to be confirmed that agma-
tine is indeed an endogenous imidazoline ligand [30–32]. clonidine and oxymetazoline inhibit 8CPTcAMP-stimu-
lated Pu [4], indicating that these agents induce inhibitionIf agmatine inhibits AVP-stimulated Pu via an imidazo-
line receptor, then antagonists selective for imidazoline via post-cAMP–dependent events. Unfortunately, evi-
dence for G-protein coupling of imidazoline receptorsreceptors should reverse the inhibition and non-imidazo-
line selective,2-antagonists should not. Three antagonists is inconclusive [41, 42]. In addition, cellular signaling is
undefined; however, arachidonic acid and prostaglandinsconsidered to be in the latter category include rauwolscine,
yohimbine, and RX821002 [5, 33, 34]. Of these, only rau- appear to have a role as cellular messengers with imida-
zoline-mediated action [43]. Previous data demonstratingwolscine reversed the inhibition (Fig. 5) whereas three out
of three antagonists considered in the former category that prostaglandins participate in the post-cAMP–depen-
dent events of clonidine and oxymetazoline-induced inhi-[35, 36]—idazoxan, atipamezole, and BU239—reversed
inhibition (Fig. 6). While rauwolscine has been consid- bition of cAMP-stimulated transport in the IMCD could
be related to imidazoline-mediated cellular events in theered a selective 2 antagonist, Molderings, Hentrich and
Go¨thert suggested that in the micromolar range rauwol- IMCD [4]. However, they do not appear to be involved
with agmatine-induced inhibition. Two other imidazo-scine possesses antagonistic properties at imidazoline re-
ceptors [37]. Our study used rauwolscine at 1 mol/L, line-selective agents (rilmenidine and harmane) failed
to inhibit AVP-stimulated Pu (data not shown). Thus,which conceivably could antagonize imidazoline recep-
tors in the IMCD. Furthermore, rauwolscine produced overall our findings do not support a specific and separate
imidazoline-receptor-mediated mechanism affecting Pu.the least amount of reversal of agmatine-induced inhibi-
tion (30% vs. 38% for atipamezole, 40% for idazoxan, As stated earlier, the observation that agmatine inhib-
its AVP-stimulated Pu but not Pf is surprising, as is theand 44% for BU239). It is interesting that the prototypical
2 antagonist yohimbine failed completely to reverse inhi- observation that dexmedetomidine demonstrates the op-
posite effects [6]. Much evidence has been obtained withbition. These findings support the involvement of at least
some component of an imidazoline-mediated mechanism. regard to the AVP-stimulated insertion of aquaporin-2
(the AVP-dependent water channel) from cellular vesi-We used the antagonists at 1 mol/L to match the
1 mol/L agmatine concentration. This agmatine level cles into the apical membrane of collecting duct cells
[44–46]. Since AVP increases both Pf and Pu in the IMCDmaximally inhibited Pu based on the observation that
100 mol/L agmatine produced the same level of inhibi- via cAMP elevation, it seems reasonable to expect that
vesicular trafficking of the urea transporter occurs liketion in the epinephrine protocol (Fig. 4C). Most 2 ago-
nists and antagonists significantly affect AVP-stimulated that for aquaporin-2. However, Inoue et al reported that
the urea transporter in the IMCD is not regulated viatransport in the nanomolar range [4, 8, 38]. It is unlikely
that experiments measuring the dose-responses of the these same trafficking mechanisms [47]. In addition,
Nielsen and Knepper demonstrated that AVP-activationantagonists would have provided valuable information
on distinguishing imidazoline versus 2-adrenergic mech- of water channels in the rat IMCD is distinct from that
of urea transporters [48]. Thus, it is reasonable that theanism with the isolated perfused tubule technique. How-
ever, dose-response pharmacological binding of the agents inhibition of AVP-stimulated water and urea transport
occurs via distinct mechanisms as well.such as radioligands on membrane preparations from the
IMCD would provide important information on ligand In summary, agmatine inhibited AVP-stimulated Pu
in the rat IMCD but did not reduce 8CPTcAMP-stimu-selectivity. It is difficult to distinguish between the2-adren-
ergic and imidazoline mechanisms. Investigators stress lated Pu. The agmatine-induced inhibition could not be
separated completely from inhibition produced by the non-caution when interpreting data from pharmacological
binding as well as physiological studies using agonists and imidazoline catecholamine epinephrine. Three of three
2/imidazoline-selective antagonists reversed agmatine-antagonists that possess some degree of cross-selectivity
among different receptors. Molecular cloning of the imi- induced inhibition whereas only one of three2-adrenergic,
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and agmatine induce histamine release from the rat stomach. Nau-non-imidazoline-selective antagonists produced a reversal.
nyn-Schmiedeberg’s Arch Pharmacol 360:711–714, 1999
We conclude that agmatine inhibits urea absorption in 17. Sener A, Lebrun P, Blachier F, et al: Stimulus-secretion coupling
of arginine-induced insulin release. Biochem Pharmacol 38:327–the terminal IMCD via an unknown receptor-mediated
330, 1989mechanism that is cAMP-dependent. While a separate
18. Lortie MJ, Novotny WF, Peterson OW, et al: Agmatine, a bioac-
imidazoline receptor is not likely, agmatine-induced inhi- tive metabolite of arginine. J Clin Invest 97:413–420, 1996
19. Lortie MJ, Ishizuka S, Schwartz D, et al: Bioactive products ofbition of AVP-stimulated Pu could involve co-localization
arginine in sepsis: Tissue and plasma composition after LPS andof 2 adrenoceptor and imidazoline receptor, or an un- iNOS blockade. Am J Physiol Cell Physiol 278:C1191–C1199, 2000
identified agmatine-selective receptor. 20. Penner SB, Smyth DD: Natriuresis following central and periph-
eral administration of agmatine in the rat. Pharmacology 53:160–
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